Targeting B cells for the treatment of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 5, Issue SUPPL. 4, 2003, Pages

  Oligino, Thomas J ^a   Dalrymple, Stacie A ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Arthritis; Autoimmunity; B cells

Indexed keywords

ALPHA CHEMOKINE; ANTIRHEUMATIC AGENT; BRUTON TYROSINE KINASE; CD19 ANTIGEN; CD20 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR5; CHIMERIC ANTIBODY; HUMAX CD20; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELL TYPE; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; HUMAN; LYMPHOCYTE DEPLETION; MOLECULAR BIOLOGY; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TARGET CELL; TREATMENT OUTCOME; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHEMOKINES, CXC; HUMANS; IMMUNOLOGIC FACTORS; MEMBRANE PROTEINS; PROTEIN-TYROSINE KINASES; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1242285497     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Frestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
2. Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002, 61:883-888.
3. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
4. Boye J, Elter T, Engert A: An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003, 14:520-535.
5. Riley JK, Sliwkowski MX: CD20: a gene in search of a function. Semin Oncol 2000, Suppl 12:17-24.
6. Johnson P, Glennie M: The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003, Suppl 2:3-8.
7. Johnson PW, Glennie MJ: Rituximab: mechanisms and applications. Br J Cancer 2001, 85:1619-1623.
8. Lonberg N, Huszar D: Human antibodies from transgenic mice. Int Rev Immunol 1995, 13:65-93.
9. Tedder TF, Isaacs CM: Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol 1989, 143:712-717.
10. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC: A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
11. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dorken B, Bargou RC: Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003, 17:900-909.
12. Niiro H, Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2:945-956.
13. Satterthwaite AB, Witte ON: The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000, 175:120-127.
14. Gold MR: To make antibodies or not: signaling by the B-cell antigen receptor. Trends Pharmacol Sci 2002, 23:316-324.
15. Mohamed AJ, Nore BF, Christensson B, Smith CI: Signalling of Bruton's tyrosine kinase, Btk. Scand J Immunol 1999, 49:113-118.
16. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, Belmont W, Cooper MD, Conley ME, Witte ON: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:2 79-290.
17. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, Smith E, Bentley D: The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226-233.
18. Conley ME: B cells in patients with X-linked agammaglobulinemia. J Immunol 1985, 134:3070-3074.
19. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG, Jentiins NA, Witte OE: Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993, 261:358-361.
20. Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE: Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993, 261:355-358.
21. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON: Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci USA 1997, 94:13152-13157.
22. Fujimoto M, Poe JC, Inaoki M, Tedder TF: CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 1998, 10:267-277.
23. Tedder TF, Sato S, Poe JC, Fujimoto M: CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity. Keio J Med 2000, 49:1-13.
24. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF: CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000, 13:47-57.
25. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF: CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996, 157:4371-4378.
26. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
27. Tsuchiya N, Ohashi J, Tokunaga K: Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev 2002, 190:169-181.
28. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
29. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
30. Mackay F, Browning JL: BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
31. Mackay F, Mackay CR: The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trend Immunol 2002, 23: 113-115.
32. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
33. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, Van G, Ross L, Delaney J, Wang L, Lacey D, Boyle WJ, Hsu H: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375.
34. Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44: 1313-1319.
35. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
36. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000, 192:953-964.
37. Kim CH, Broxmeyer HE: Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 1999, 65:6-15.
38. Luster AD: The role of chemokines in linking innate-and adaptive immunity. Curr Opin Immunol 2002, 14:129-135.
39. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B: B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphold tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998, 187:655-660.
40. Pevzner V, Wolf I, Burgstahler R, Forster R, Lipp M: Regulation of expression of chemokine receptor BLR1/CXCR5 during B cell maturation. Curr Top Microbiol Immunol 1999, 246:79-84; discussion 85.
41. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG: A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314.
42. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M: A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996, 87:1037-1047.
43. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM: Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
44. Weyand CM, Braun A, Takemura S, Goronzy JJ: Lymphoid microstructures in rheumatoid synovitis. Curr Dir Autoimmunol 2001, 3:168-187.
45. Weyand CM, Goronzy JJ: Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci 2003, 987:140-149.
46. Schroder AE, Greiner A, Seyfert C, Berek C: Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996, 93:221-225.
47. + T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol 1998, 161:6390-6397.
48. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM: T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
49. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T: Lymphoid chemokine B cell-attracting chemokine-1 (CXCL 13): expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001, 166:650-655.